| Assay ID | Title | Year | Journal | Article |
|---|
| AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | | | |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
| Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4
| A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347411 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
| High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID734676 | Toxicity in C57BL/6J mouse assessed as body weight at 300 mg/kg, po bid for 12 to 13 days measured on day 10 (Rvb = 23.2 +/-0.4 gms) | 2013 | European journal of medicinal chemistry, Apr, Volume: 62 | Rational design and synthesis of 4-substituted 2-pyridin-2-ylamides with inhibitory effects on SH2 domain-containing inositol 5'-phosphatase 2 (SHIP2). |
| AID734677 | Antidiabetic activity in db/db mouse assessed as decrease in HOMA-R index of insulin resistance at 300 mg/kg, po bid for 12 to 13 days | 2013 | European journal of medicinal chemistry, Apr, Volume: 62 | Rational design and synthesis of 4-substituted 2-pyridin-2-ylamides with inhibitory effects on SH2 domain-containing inositol 5'-phosphatase 2 (SHIP2). |
| AID1829587 | Inhibition of human SHIP2 catalytic domain (419 to 832 residues) phosphatase activity assessed as inhibition of Ins(1,3,4,5)P4 production using Ins(1,3,4,5)P4 as substrate incubated for 20 mins measured using microplate reader | 2021 | Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7
| Allosteric Site on SHIP2 Identified Through Fluorescent Ligand Screening and Crystallography: A Potential New Target for Intervention. |
| AID1829585 | Inhibition of 2-FAM-InsP5 binding to human SHIP2 catalytic domain (419 to 832 residues) assessed as change in polarization by fluorescence polarization based displacement assay | 2021 | Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7
| Allosteric Site on SHIP2 Identified Through Fluorescent Ligand Screening and Crystallography: A Potential New Target for Intervention. |
| AID1829590 | Inhibition of human SHIP2 (419 to 732 residues) expressed in Escherichia coli by malachite green phosphate assay | 2021 | Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7
| Allosteric Site on SHIP2 Identified Through Fluorescent Ligand Screening and Crystallography: A Potential New Target for Intervention. |
| AID734683 | Inhibition of SHIP2 (unknown origin) | 2013 | European journal of medicinal chemistry, Apr, Volume: 62 | Rational design and synthesis of 4-substituted 2-pyridin-2-ylamides with inhibitory effects on SH2 domain-containing inositol 5'-phosphatase 2 (SHIP2). |
| AID734674 | Toxicity in C57BL/6J mouse assessed as epididymal white adipose tissue weight at 300 mg/kg, po bid for 12 to 13 days measured on day 15 (Rvb = 0.03 +/-0.0 gms) | 2013 | European journal of medicinal chemistry, Apr, Volume: 62 | Rational design and synthesis of 4-substituted 2-pyridin-2-ylamides with inhibitory effects on SH2 domain-containing inositol 5'-phosphatase 2 (SHIP2). |
| AID734669 | Toxicity in db/db mouse assessed as liver weight at 300 mg/kg, po bid for 12 to 13 days measured on day 12 to 13 (Rvb = 1.57 +/-0.04 gms) | 2013 | European journal of medicinal chemistry, Apr, Volume: 62 | Rational design and synthesis of 4-substituted 2-pyridin-2-ylamides with inhibitory effects on SH2 domain-containing inositol 5'-phosphatase 2 (SHIP2). |
| AID734239 | Decrease in PEPCK gene expression in db/db mouse liver at 300 mg/kg, po bid for 12 to 13 days by real time RT-PCR analysis | 2013 | European journal of medicinal chemistry, Apr, Volume: 62 | Rational design and synthesis of 4-substituted 2-pyridin-2-ylamides with inhibitory effects on SH2 domain-containing inositol 5'-phosphatase 2 (SHIP2). |
| AID734672 | Toxicity in C57BL/6J mouse assessed as fasting plasma glucose level at 300 mg/kg, po bid for 12 to 13 days measured on day 15 (Rvb = 78 +/-6 mg/dl) | 2013 | European journal of medicinal chemistry, Apr, Volume: 62 | Rational design and synthesis of 4-substituted 2-pyridin-2-ylamides with inhibitory effects on SH2 domain-containing inositol 5'-phosphatase 2 (SHIP2). |
| AID1829592 | Inhibition of SHIP2 in serum-starved mouse Mm1 cells assessed as reduction in Akt phosphorylation incubated for 30 mins by Western blot analysis | 2021 | Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7
| Allosteric Site on SHIP2 Identified Through Fluorescent Ligand Screening and Crystallography: A Potential New Target for Intervention. |
| AID734668 | Toxicity in db/db mouse assessed as food intake at 300 mg/kg, po bid for 12 to 13 days measured on day 10 (Rvb = 6.06 +/-0.36 gms/day) | 2013 | European journal of medicinal chemistry, Apr, Volume: 62 | Rational design and synthesis of 4-substituted 2-pyridin-2-ylamides with inhibitory effects on SH2 domain-containing inositol 5'-phosphatase 2 (SHIP2). |
| AID1829589 | Cytotoxicity against IL-6 treated mouse Mm1 cells assessed as reduction in cell survival measured at 1 to 10 uM after 24 hrs | 2021 | Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7
| Allosteric Site on SHIP2 Identified Through Fluorescent Ligand Screening and Crystallography: A Potential New Target for Intervention. |
| AID734670 | Toxicity in db/db mouse assessed as body weight at 300 mg/kg, po bid for 12 to 13 days measured on day 10 (Rvb = 39.2 +/-0.6 gms) | 2013 | European journal of medicinal chemistry, Apr, Volume: 62 | Rational design and synthesis of 4-substituted 2-pyridin-2-ylamides with inhibitory effects on SH2 domain-containing inositol 5'-phosphatase 2 (SHIP2). |
| AID734238 | Decrease in glucose-6-phosphatase gene expression in db/db mouse liver at 300 mg/kg, po bid for 12 to 13 days by real time RT-PCR analysis | 2013 | European journal of medicinal chemistry, Apr, Volume: 62 | Rational design and synthesis of 4-substituted 2-pyridin-2-ylamides with inhibitory effects on SH2 domain-containing inositol 5'-phosphatase 2 (SHIP2). |
| AID734666 | Toxicity in C57BL/6J mouse assessed as effect on glucose tolerance at 300 mg/kg, po bid for 13 days by glucose tolerance test | 2013 | European journal of medicinal chemistry, Apr, Volume: 62 | Rational design and synthesis of 4-substituted 2-pyridin-2-ylamides with inhibitory effects on SH2 domain-containing inositol 5'-phosphatase 2 (SHIP2). |
| AID734675 | Toxicity in C57BL/6J mouse assessed as food intake at 300 mg/kg, po bid for 12 to 13 days measured on day 10 (Rvb = 3.72 +/-0.23 gms/day) | 2013 | European journal of medicinal chemistry, Apr, Volume: 62 | Rational design and synthesis of 4-substituted 2-pyridin-2-ylamides with inhibitory effects on SH2 domain-containing inositol 5'-phosphatase 2 (SHIP2). |
| AID734671 | Toxicity in C57BL/6J mouse assessed as serum insulin level at 300 mg/kg, po bid for 12 to 13 days measured on day 15 (Rvb = 0.25 +/-0.11 ng/ml) | 2013 | European journal of medicinal chemistry, Apr, Volume: 62 | Rational design and synthesis of 4-substituted 2-pyridin-2-ylamides with inhibitory effects on SH2 domain-containing inositol 5'-phosphatase 2 (SHIP2). |
| AID734680 | Inhibition of SHIP2 in TNF alpha-treated Sprague-Dawley rat cortical neuron assessed as potentiation of insulin-stimulated Akt phosphorylation at Thr308 at 10 uM treated for 15 mins after TNF alpha challenge for 3 days and prior to insulin stimulation mea | 2013 | European journal of medicinal chemistry, Apr, Volume: 62 | Rational design and synthesis of 4-substituted 2-pyridin-2-ylamides with inhibitory effects on SH2 domain-containing inositol 5'-phosphatase 2 (SHIP2). |
| AID734679 | Antidiabetic activity in db/db mouse assessed as serum insulin level at 300 mg/kg, po bid for 12 to 13 days measured on day 12 to 13 (Rvb = 7.30 +/-1.10 ng/ml) | 2013 | European journal of medicinal chemistry, Apr, Volume: 62 | Rational design and synthesis of 4-substituted 2-pyridin-2-ylamides with inhibitory effects on SH2 domain-containing inositol 5'-phosphatase 2 (SHIP2). |
| AID1829586 | Inhibition of human SHIP2 catalytic domain (419 to 832 residues) phosphatase activity assessed as phosphate release using Ins(1,3,4,5)P4 as substrate incubated for 20 mins measured using microplate reader | 2021 | Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7
| Allosteric Site on SHIP2 Identified Through Fluorescent Ligand Screening and Crystallography: A Potential New Target for Intervention. |
| AID734678 | Antidiabetic activity in db/db mouse assessed as fasting plasma glucose level at 300 mg/kg, po bid for 12 to 13 days measured on day 12 to 13 (Rvb = 106 +/-6 mg/dl) | 2013 | European journal of medicinal chemistry, Apr, Volume: 62 | Rational design and synthesis of 4-substituted 2-pyridin-2-ylamides with inhibitory effects on SH2 domain-containing inositol 5'-phosphatase 2 (SHIP2). |
| AID734681 | Inhibition of SHIP2 in TNF alpha-treated mouse 3T3L1 cells assessed as potentiation of insulin-stimulated Akt phosphorylation at Thr308 at 10 uM treated for 15 mins after TNF alpha challenge for 16 hrs and prior to insulin stimulation measured after 2 hrs | 2013 | European journal of medicinal chemistry, Apr, Volume: 62 | Rational design and synthesis of 4-substituted 2-pyridin-2-ylamides with inhibitory effects on SH2 domain-containing inositol 5'-phosphatase 2 (SHIP2). |
| AID734240 | Antidiabetic activity in db/db mouse assessed as decrease in glucose area under curve at 300 mg/kg, po bid for 10 days by glucose tolerance test relative vehicle treated control | 2013 | European journal of medicinal chemistry, Apr, Volume: 62 | Rational design and synthesis of 4-substituted 2-pyridin-2-ylamides with inhibitory effects on SH2 domain-containing inositol 5'-phosphatase 2 (SHIP2). |
| AID734241 | Antidiabetic activity in db/db mouse assessed as decrease in glucose intolerance at 300 mg/kg, po bid for 10 days by glucose tolerance test | 2013 | European journal of medicinal chemistry, Apr, Volume: 62 | Rational design and synthesis of 4-substituted 2-pyridin-2-ylamides with inhibitory effects on SH2 domain-containing inositol 5'-phosphatase 2 (SHIP2). |
| AID734667 | Toxicity in db/db mouse assessed as epididymal white adipose tissue weight at 300 mg/kg, po bid for 12 to 13 days measured on day 12 to 13 (Rvb = 1.82 +/-0.1 gms) | 2013 | European journal of medicinal chemistry, Apr, Volume: 62 | Rational design and synthesis of 4-substituted 2-pyridin-2-ylamides with inhibitory effects on SH2 domain-containing inositol 5'-phosphatase 2 (SHIP2). |
| AID734673 | Toxicity in C57BL/6J mouse assessed as liver weight at 300 mg/kg, po bid for 12 to 13 days measured on day 15 (Rvb = 0.74 +/-0.03 gms) | 2013 | European journal of medicinal chemistry, Apr, Volume: 62 | Rational design and synthesis of 4-substituted 2-pyridin-2-ylamides with inhibitory effects on SH2 domain-containing inositol 5'-phosphatase 2 (SHIP2). |
| AID1345394 | Human INPPL1 (Inositol polyphosphate phosphatases) | 2009 | British journal of pharmacology, Oct, Volume: 158, Issue:3
| Discovery and functional characterization of a novel small molecule inhibitor of the intracellular phosphatase, SHIP2. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |